Wordt geladen...
Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab
BACKGROUND: Management of disease-modifying therapies in Multiple Sclerosis (MS) during the COVID-19 pandemic is a controversial issue. Alemtuzumab is an immunosuppressive drug that induces lymphocytes depletion. In this study, we aimed to evaluate the frequency and severity of COVID-19 in a case se...
Bewaard in:
| Gepubliceerd in: | Mult Scler Relat Disord |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Elsevier B.V.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7286822/ https://ncbi.nlm.nih.gov/pubmed/32554284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102297 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|